What Is Insulin?

Insulin is a peptide hormone produced by the beta cells of the pancreatic islets of Langerhans that regulates blood glucose concentration by facilitating the uptake of glucose into muscle, adipose, and liver cells. It is a 51-amino-acid protein composed of two polypeptide chains, A and B, linked by disulfide bridges, and is cleaved from a precursor molecule, proinsulin, during secretion. Insulin is the primary anabolic signal in mammalian metabolism: its presence suppresses hepatic glucose output, promotes glycogen synthesis, and stimulates cellular glucose transport through the GLUT4 transporter. Its deficiency or impaired action is the defining biochemical lesion in diabetes mellitus, one of the most prevalent chronic diseases globally.

From an engineering perspective, insulin occupies a central position in biomedical device development. The need to measure glucose and deliver insulin precisely and continuously has driven decades of work in biosensor design, microfluidics, control theory, and implantable device engineering. The biomedical engineering community, including IEEE's Engineering in Medicine and Biology Society, engages extensively with insulin as both a biological signal and a therapeutic agent requiring automated management systems.

Biosynthesis and Secretion

Insulin biosynthesis begins with the transcription of the INS gene in pancreatic beta cells, producing preproinsulin, which is processed to proinsulin in the endoplasmic reticulum and then cleaved to insulin and C-peptide in secretory granules. Glucose-stimulated insulin secretion depends on the mitochondrial metabolism of glucose within the beta cell: oxidative phosphorylation raises the ATP-to-ADP ratio, which closes ATP-sensitive potassium channels, depolarizing the cell membrane and triggering calcium influx that causes granule exocytosis. This tight stoichiometric coupling between glucose concentration and secretion rate means that in healthy individuals the blood insulin level tracks postprandial glucose rises and returns to basal within 90 to 120 minutes. Hormonal co-regulators including glucagon-like peptide-1 (GLP-1) potentiate glucose-stimulated secretion through cyclic AMP pathways.

Mechanism of Action

Insulin acts by binding to the insulin receptor, a transmembrane tyrosine kinase heterotetrameric protein expressed on target cells. Receptor binding triggers autophosphorylation and activation of a phosphorylation cascade through insulin receptor substrate proteins (IRS-1, IRS-2), PI3-kinase, and Akt, ultimately causing GLUT4-containing vesicles to fuse with the plasma membrane and increase glucose uptake capacity by an order of magnitude. In the liver, the same signaling cascade suppresses gluconeogenesis and activates glycogen synthase. Insulin resistance, in which target cells require supraphysiological insulin concentrations to achieve normal glucose uptake, is the central defect in type 2 diabetes and is associated with obesity-driven inflammation, ectopic lipid accumulation, and mitochondrial dysfunction.

Biomedical Engineering and Delivery Systems

The engineering challenge of insulin delivery is to replicate the physiological pattern of secretion using external devices, a goal that has motivated the development of subcutaneous insulin pumps, continuous glucose monitors (CGM), and closed-loop artificial pancreas systems. Research on wearable glucose biosensors published in Frontiers in Bioengineering and Biotechnology reviews enzymatic and non-enzymatic sensor architectures designed to monitor interstitial glucose with the accuracy and stability needed to drive insulin dosing algorithms. Model predictive control (MPC) algorithms, tuned to individual insulin pharmacokinetics, translate CGM glucose readings into pump delivery commands; design studies for dual-hormone artificial pancreas controllers at NIH demonstrate that co-delivery of insulin and glucagon reduces hypoglycemia risk compared with insulin-only closed-loop systems. Advances in insulin aptasensor technology reviewed in Annals of Biomedical Engineering describe electrochemical and optical detection platforms capable of quantifying insulin concentrations in sub-nanomolar ranges relevant to clinical monitoring.

Applications

Insulin has applications in a wide range of biomedical engineering and clinical systems, including:

• Subcutaneous insulin pump therapy and implantable insulin delivery devices
• Continuous glucose monitoring and closed-loop artificial pancreas systems
• Electrochemical and optical biosensors for plasma insulin quantification
• In vitro diagnostic platforms for diabetes research and drug screening
• Pharmacokinetic modeling for insulin analog drug development